facebook
Subscribe50$/product give away!


Submit an Article to Pharmacy HQ     
Please include the author's name, title, and citations.     

ACD SOLUTION MODIFIED solution


  1. No Title 1572552743
  2. No Title 1572450750
  3. Description
  4. Clinical Pharmacology
  5. Indications And Usage
  6. Contraindications
  7. Dosage And Administration
  8. Package Label.principal Display Panel

No Title 1572552743 

Per your order, we have compounded ACD Solution Modified as a solution of 10 mL in a 100 mL vial. The characteristics of this compounded preparation are as follows

No Title 1572450750 

Per your order, we have compounded ACD Solution Modified as a solution of 10 mL in a 100 mL vial. The characteristics of this compounded preparation are as follows

Description  

Each 100 mL vial contains 80 mg citric acid, 224 mg sodium citrate anhydrous, and 120 mg dextrose anhydrous in a sterile, non-pyrogenic solution of 10 mL. The pH of the solution has been adjusted to be between 4.5 to 5.5

Clinical Pharmacology  

In vitro, citrate ions combine with ionic calcium in the blood and the resulting

lack of ionic calcium prevents coagulation. Blood that has been treated with citrate anticoagulants is nontoxic to the body when injected in small amounts intravenously. After injection, citrate ions are rapidly removed from the blood by the liver, polymerized into glucose, and then metabolized in the usual manner

Indications And Usage  

ACD solution modified is to be used in the labeling of red blood cells for intravenous administration with Cr-51 Sodium Chromate.

Contraindications  

There are no known contraindications.

Dosage And Administration  

Red Blood Cell Labeling Procedure

  1. Labeling may be performed without washing or centrifugation steps directly in the reaction vial.
  2. A 30 to 50 mL sample of whole blood is withdrawn from the patient and added aseptically to a vial of ACD Solution Modified.
  3. 50 to 150 microcuries of Sodium Chromate 51 is then injected into the reaction vial using a shielded syringe. The amount of radioactivity added to the vial will

    depend on the intended use of the labeled red blood cells.

  4. The suspension is incubated for 30 to 60 minutes at room temperature with frequent, gentle agitation.
  5. After incubation, 100 mg Ascorbic Acid Injection is injected into the vial. The ascorbic acid reduces any remaining unbound dianionic chromium 51 to the anionic state which does not penetrate red blood cells; thus in vivo labeling of red blood cells is prevented.

Storage and Handling

Store the product at room temperature

Package Label.principal Display Panel  

Figure 1

C:\Users\achai\Desktop\NDC Project-AC 2012\ACD\ACD Label.JPG
ACD SOLUTION MODIFIED
acd solution modified solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:51808-201
Route of Administration INTRAVENOUS
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
ANHYDROUS CITRIC ACID (UNII: XF417D3PSL) (ANHYDROUS CITRIC ACID - UNII:XF417D3PSL) ANHYDROUS CITRIC ACID 8 mg in 1 mL
Inactive Ingredients
Ingredient Name Strength
ANHYDROUS TRISODIUM CITRATE (UNII: RS7A450LGA) 22.4 mg in 1 mL
ANHYDROUS DEXTROSE (UNII: 5SL0G7R0OK) 12 mg in 1 mL
Packaging
# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:51808-201-01 10 mL in 1 VIAL
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
Unapproved drug other 05/23/2012
Labeler - AnazaoHealth Corporation (011038762)
Establishment
Name Address ID/FEI Business Operations
AnazaoHealth Corporation 011038762 MANUFACTURE

Revised: 5/2012 AnazaoHealth Corporation



Your use of this website constitutes your agreement to the terms and conditions linked below:
Terms and Conditions | Resources
2017 © Copyright PharmacyHQ.com. Questions?
Please contact: pharmacyhq.mail@gmail.com